Only the 45 patients with definite LAM by ERS criteria were included in the comparison of biomarkers in LAM and controls: those with probable LAM were used to determine the utility of VEGF-D for diagnosis. This evidence concerns the gene VEGFD and lymphangioleiomyomatosis.